-
Mashup Score: 0Full Schedule - 10 month(s) ago
Session IV: ESMO Session: Focus on Young Oncologists (YO) in Collaboration With ESMO Young Oncologist Committee (YOC)Session Chair: Andrés Cervantes, MD, PhD – Biomedical Research institute INCLIVA, University of Valencia, Hospital Clínico de ValenciaSession Chair: Deniz Can Güven, MD – Hacettepe University Cancer InstituteSession Chair: Rille Pihlak, MD, PhD – St Bart’s Hospital
Source: wgi2023.eventscribe.netCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Systemic chemotherapy did not show any benefit in patients with inoperable low-grade mucinous appendiceal adenocarcinoma.
Source: Docwire NewsCategories: Latest Headlines, Partners & KOLsTweet-
Systemic chemotherapy did not show any benefit in patients with inoperable low-grade mucinous appendiceal #adenocarcinoma. https://t.co/03xmJbwGaq https://t.co/Lni2vAS6av
-
-
Mashup Score: 0Wolters Kluwer Health - 11 month(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Researchers presented data at #AACR23 from a study that sought to develop a model for predicting which patients would experience a pathological complete response after trimodality therapy for their esophageal and gastroesophageal junction #adenocarcinoma. https://t.co/H52MCypPpb https://t.co/VQFSHsjGLQ
-
-
Mashup Score: 0
Dr. Suneel Kamath from the Cleveland Clinic – Young onset colorectal cancer (yoCRC) has been increasing over the past few decades, and the reasons behind this rise are still not well understood. Dr. Suneel Kamath and his team conducted a study using metabolomics to gain insights into the underlying factors contribut…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
📣 ASCO 2023 🧪🔬 Dr. @SKamath_MD, from @CleClinicMD, discusses the #ASCO23 abstract that is unraveling the #metabolomic differences between young-onset and average-onset #colorectal #adenocarcinoma (CRC). 🎯🩺 🔗 https://t.co/sb6h7w8d1F https://t.co/1vXZcgIgPy
-
-
Mashup Score: 0Wolters Kluwer Health - 12 month(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Zolbetuximab + chemotherapy can be a potential new standard of care for patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic #gastric/gastroesophageal junction #adenocarcinoma. @ASCO @WeillCornell https://t.co/ZFmh2Smkgi https://t.co/Blaq3tG2Ed
-
-
Mashup Score: 1Source: link.springer.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Validation of a #Resectability Scoring System for Prediction of #Pancreatic #Adenocarcinoma Surgical Outcomes @DiegoToesca @MayoClinic https://t.co/WT4cNQq7Ov #VisualAbstract @McMastersKelly https://t.co/NYkGZS0f9a
-
-
Mashup Score: 0Wolters Kluwer Health - 12 month(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Zolbetuximab + chemotherapy can be a potential new standard of care for patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic #gastric/gastroesophageal junction #adenocarcinoma. @ASCO @WeillCornell https://t.co/ZFmh2Smkgi https://t.co/uueekd1voG
-
-
Mashup Score: 0
BackgroundAlthough anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK-TKIs) have impressive response in advanced lung adenocarcinoma with anaplastic lymphoma kinase (ALK) fusion, no guidelines point to the potential benefits of neoadjuvant ALK-TKIs for N3 unresectable locally advanced lung cancer. Current ongoing clinical trials mainly focus on the efficacy of neoadjuvant ALK-TKIs in…
Source: FrontiersCategories: Latest Headlines, PulmonologyTweet-
#Casereport: Complete #pathological admission in N3 unresectable locally advanced #lung #adenocarcinoma with a novel INTS10-ALK and EML4-ALK fusion after #neoadjuvant #crizotinib https://t.co/tLZ3RwIpc1 https://t.co/bbSvZ4bfCv
-
-
Mashup Score: 2Source: link.springer.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Change Impact of Body Composition During #Neoadjuvant #Chemoradiotherapy in Patients with Resectable and Borderline Resectable #Pancreatic Ductal #Adenocarcinoma Undergoing #Pancreatectomy https://t.co/VrVNk0cvfp #VisualAbstract @McMastersKelly https://t.co/J5URuHMdbA
-
-
Mashup Score: 2PTEN Loss Expands the Histopathologic Diversity and Lineage Plasticity of Lung Cancers Initiated by Rb1/Trp53 Deletion - 1 year(s) ago
High-grade neuroendocrine tumors of the lung such as SCLC are recalcitrant cancers for which more effective systemic therapies are needed. Despite their histopathologic and molecular heterogeneity, they are generally treated as a single disease entity with similar chemotherapy regimens. Whereas marked clinical responses can be observed, they are short-lived. Inter- and intratumoral heterogeneity…
Source: Journal of Thoracic OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The results of this study identify #Pten loss as clinically relevant in driving the molecular and histopatholgical heterogeneity of neuroendocrine (#NE) lung tumors from #adenocarcinoma to #SCLC. https://t.co/KtsUFJMrAd #LCSM https://t.co/s39gvXeazV
-
Looking forward to Elizabeth Smyth's #WCGIC2023 presentation about EORTC's 1707 VESTIGE trial on gastroesophageal #Adenocarcinoma today at 10:20 AM. Programme: https://t.co/flS7eFxgo3 @WCGIC #CancerResearch #ClinicalTrials https://t.co/GzJRjuRTMm